Correction: Stewart, E.R.; Thompson, G.R. Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence. J. Fungi 2016, 2, 25. by Stewart, Ethan R & Thompson, George R
UC Davis
UC Davis Previously Published Works
Title
Correction: Stewart, E.R.; Thompson, G.R. Treatment of Primary Pulmonary Aspergillosis: 





















Correction: Stewart, E.R.; Thompson, G.R. Treatment
of Primary Pulmonary Aspergillosis: An Assessment
of the Evidence. J. Fungi 2016, 2, 25.
Ethan R. Stewart 1 and George R. Thompson III 1,2,*
1 Department of Internal Medicine, Division of Infectious Diseases, Davis Medical Center, 4150 V Street,
Suite G500, Sacramento, CA 95817, USA; ethanstewart@gmail.com
2 Department of Medical Microbiology and Immunology, University of California, Rm. 3138, Tupper Hall,
One Shields Ave, Davis, CA 95616, USA
* Correspondence: grthompson@ucdavis.edu; Tel.: +1-916-734-3815; Fax: +1-530-752-8692
Academic Editor: William J. Steinbach
Received: 3 November 2016; Accepted: 4 November 2016; Published: 4 November 2016
The authors of the published paper [1] would like to correct Table 1. The sixth row in the
second column should have been Amphotericin B Lipid Complex (ABLC). Therefore, Table 1 should
read as follows:
Table 1. Treatment recommendations for invasive aspergillosis.
Recommendation Drug Dosing Comments
Primary Voriconazole 6 mg/kg IV every 12 h timestwo then 4 mg/kg IV every 12 h
Oral therapy at mg/kg
dosing or 200–300 mg











Vorizonazole as above plus
Anidulafungin 200 mg IV daily
times one then 100 mg IV daily
Combination therapy




Complex (ABLC) 5 mg/kg/day IV
Secondary Caspofungin 70 mg IV daily times one then50 mg IV daily Monotherapy as salvage
Posaconazole
Oral suspension: 200 mg PO
every 8 h, Tablet: 300 mg PO
every 12 h times two then
300 mg PO daily, Intravenous:
300 mg IV every 12 h
times two then 300 mg IV daily
Caution in use of tablet
formulation with acid
suppression; TDM required
Itraconazole 200 mg PO every 12 h TDM required
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We apologize for any inconvenience caused to readers. The manuscript will be updated and the
original will remain available on the article webpage.
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